Drug Profile
Research programme: melanocortin-4 receptor modulators - Neurocrine Biosciences
Latest Information Update: 24 Feb 2011
Price :
$50
*
At a glance
- Originator Neurocrine Biosciences
- Class Amides; Benzylamines; Piperazines
- Mechanism of Action Melanocortin type 4 receptor agonists; Melanocortin type 4 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Anxiety disorders; Cachexia; Erectile dysfunction; Obesity; Pain
Most Recent Events
- 10 Jul 2006 No development reported - Preclinical for Anxiety disorders in USA (unspecified route)
- 10 Jul 2006 No development reported - Preclinical for Cachexia in USA (unspecified route)
- 10 Jul 2006 No development reported - Preclinical for Erectile dysfunction in USA (unspecified route)